Novavax (Germany) Top Insiders
NVV1 Stock | EUR 8.38 0.53 5.95% |
Novavax employs about 1.5 K people. The company is managed by 33 executives with a total tenure of roughly 171 years, averaging almost 5.0 years of service per executive, having 46.7 employees per reported executive. Examination of Novavax's management performance can provide insight into the company performance.
Stanley Erck CEO President, Chief Executive Officer, Director |
Rick Crowley President Chief Operating Officer, Executive Vice President |
Novavax |
Novavax Management Team Effectiveness
The company has return on total asset (ROA) of (0.317) % which means that it has lost $0.317 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (8.982) %, meaning that it generated substantial loss on money invested by shareholders. Novavax's management efficiency ratios could be used to measure how well Novavax manages its routine affairs as well as how well it operates its assets and liabilities.Novavax Workforce Comparison
Novavax is regarded third in number of employees category among its peers. The total workforce of Biotechnology industry is now estimated at about 10,967. Novavax retains roughly 1,541 in number of employees claiming about 14% of stocks in Biotechnology industry.
The company has Profit Margin (PM) of (0.72) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.66) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.66. Novavax Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Novavax Price Series Summation is a cross summation of Novavax price series and its benchmark/peer.
Novavax Notable Stakeholders
A Novavax stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Novavax often face trade-offs trying to please all of them. Novavax's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Novavax's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Stanley Erck | President, Chief Executive Officer, Director | Profile | |
Rick Crowley | Chief Operating Officer, Executive Vice President | Profile | |
John Trizzino | Executive Vice President, Chief Business Officer, Chief Financial Officer and Treasurer | Profile | |
Gregory Covino | Chief Financial Officer, Executive Vice President | Profile | |
MBA BS | Exec Officer | Profile | |
Jody Lichaa | Senior Vice President - Quality Assurance | Profile | |
Ben Machielse | Executive Vice President - CMC | Profile | |
Michael McManus | Independent Director | Profile | |
Brian Webb | Senior Vice President - Manufacturing | Profile | |
John Herrmann | Executive Vice President Chief Legal Officer | Profile | |
Filip Dubovsky | Senior Vice President Chief Medical Officer | Profile | |
Rachel King | Independent Director | Profile | |
Gary Evans | Independent Director | Profile | |
Margaret McGlynn | Independent Director | Profile | |
Jill Hoyt | Chief Human Resource Officer, Executive Vice President | Profile | |
Erika Trahan | Associate PR | Profile | |
Henrietta Ukwu | Senior Vice President Chief Regulatory and Quality Officer | Profile | |
Frank Czworka | Senior Vice President - Global Sales | Profile | |
Gregg Alton | Director | Profile | |
James CFA | CFO VP | Profile | |
Rajiv Modi | Director | Profile | |
JD Esq | VP Officer | Profile | |
Brian Rosen | Senior Vice President - Commercial Strategy | Profile | |
Richard Crowley | Ex COO | Profile | |
Silvia Taylor | Senior Vice President of Investor Relations and Corporate Affairs | Profile | |
John III | Chief VP | Profile | |
Biegie Lee | VP Officer | Profile | |
Gale Smith | VP Scientist | Profile | |
James Young | Independent Chairman of the Board | Profile | |
Gregory Glenn | President Research and Development | Profile | |
David Mott | Independent Director | Profile | |
Madelyn Caltabiano | Senior Vice President - Global Program Management | Profile | |
Richard Douglas | Independent Director | Profile |
About Novavax Management Performance
The success or failure of an entity such as Novavax often depends on how effective the management is. Novavax management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Novavax management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Novavax management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. NOVAVAX INC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 1541 people.
Novavax Workforce Analysis
Traditionally, organizations such as Novavax use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Novavax within its industry.Novavax Manpower Efficiency
Return on Novavax Manpower
Revenue Per Employee | 743.9K | |
Revenue Per Executive | 34.7M | |
Net Loss Per Employee | 1.1M | |
Net Loss Per Executive | 52.8M |
Complementary Tools for Novavax Stock analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Fundamental Analysis View fundamental data based on most recent published financial statements |